Melfalan Teva (Melphalan Hydrochloride)

Melphalan directly alkylates DNA bases, forming cross‑links that block DNA replication and transcription. This interference triggers programmed cell death (apoptosis) in malignant cells, reducing tumor burden while sparing most normal tissues.

The dosing regimen for Melfalan Teva is individualized by the prescribing oncologist based on the specific indication, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Melphalan is classified as having unknown safety in pregnancy and is considered contraindicated for pregnant or nursing women because of its potential teratogenic and cytotoxic effects. Women of child‑bearing potential should use effective contraception during treatment and for a period thereafter as advised by their physician.

To request Melfalan Teva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melfalan (melphalan) is a nitrogen mustard alkylating agent similar to cyclophosphamide but is administered intravenously as an injection solution. Compared with oral alkylators, melphalan offers more predictable pharmacokinetics but requires careful monitoring for myelosuppression and organ toxicity.

Melfalan Teva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Melfalan Teva is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional in a clinical setting, typically over a defined period according to the treatment protocol, with appropriate pre‑medication to manage nausea and other infusion‑related reactions.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, renal impairment, pulmonary toxicity, and rare but life‑threatening cardiac events. Patients should be monitored closely for signs of infection, organ dysfunction and unexpected laboratory abnormalities.

Melfalan Teva is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant or nursing women, and in individuals with severe renal or hepatic impairment where the risk outweighs benefit. It should also be avoided in patients receiving live vaccines.